Initially employed as an approach to lower glucose in type 2 diabetics, sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors have demonstrated consistent beneficial effects in humans with heart failure independent of diabetes, and in mitigating the progression of renal disease.1, 2, 3. The gene discussed is SLC5A2; the disease is kidney disorder.